Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)

Description

The goal of this clinical trial is to compare a 2-dose and 3-dose series of 9vHPV vaccine among 27-45-year-old females to assess if 2 doses elicit a noninferior immune response. Participants will be randomized 1:1 to either the 2-dose group or the 3-dose group and asked to provide 4 blood samples over a period of 12 months. All 2-dose participants will be offered a 3rd dose after the final blood draw,12 months after their initial vaccination.

Conditions

Immunization, HPV Infection, Human Papillomavirus

Study Overview

Study Details

Study overview

The goal of this clinical trial is to compare a 2-dose and 3-dose series of 9vHPV vaccine among 27-45-year-old females to assess if 2 doses elicit a noninferior immune response. Participants will be randomized 1:1 to either the 2-dose group or the 3-dose group and asked to provide 4 blood samples over a period of 12 months. All 2-dose participants will be offered a 3rd dose after the final blood draw,12 months after their initial vaccination.

Comparison of the Immune Response After Administration of 2 vs. 3 Doses of the FDA-approved 9-Valent HPV Vaccine Among Women 27-45 Years of Age

Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)

Condition
Immunization
Intervention / Treatment

-

Contacts and Locations

Galveston

University of Texas Medical Branch, Galveston, Texas, United States, 77555

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Females 27-45 years old.
  • 2. Ability to give informed consent.
  • 3. Has not received any prior doses of the HPV vaccine. This will be verified by the person and state registry (Immtrac), as well as the person's electronic medical record.
  • 4. Reliable telephone access for the duration of the project.
  • 5. Can read and speak in either English or Spanish.
  • 6. Identified source of funding for vaccine such as Medicaid, private health insurance, Texas Healthy Women program, etc.
  • 7. Reports consistent use of reliable birth control and plans to continue its use through study month 13.
  • 1. Currently pregnant or plans to become pregnant or donate eggs in the next 13 months. Any subjects with positive pregnancy tests at the initial visit will be disqualified from the study and advised to seek prenatal care.
  • 2. Has an immunodeficiency or autoimmune disease such as HIV infection, lymphoma, leukemia, lupus, rheumatoid arthritis, inflammatory bowel disease, or other autoimmune condition.
  • 3. Currently receiving treatment or medication that can suppress immune function including radiation therapy, chemotherapy, cyclosporin, leflunomide (Arava), TNF-α antagonists, monoclonal antibody therapies (including rituximab \[Rituxan\]), intravenous gamma globulin (IVIG), antilymphocyte sera, other therapy known to interfere with the immune response, or systemic corticosteroids (by mouth or intramuscular injection). Those using or have used steroids that are inhaled, placed in the eye, applied on the skin, or injected into the joint/soft tissue will be considered eligible for the study.
  • 4. History of splenectomy
  • 5. Known allergies to any vaccine components, including aluminum, yeast or Benzonase.
  • 6. Febrile at ≥100°F in the 24 hours prior to vaccination. The patients may be rescheduled for a later date.
  • 7. History of thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections.
  • 8. History of \>10 sexual partners in their lifetime at time of enrollment
  • 9. Plans to move out of the Galveston/Houston area in the 13 months following study entry.

Ages Eligible for Study

27 Years to 45 Years

Sexes Eligible for Study

FEMALE

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

The University of Texas Medical Branch, Galveston,

Abbey B Berenson, MD, PhD, PRINCIPAL_INVESTIGATOR, University of Texas

Study Record Dates

2027-08